[go: up one dir, main page]

BR0316746A - Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) - Google Patents

Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)

Info

Publication number
BR0316746A
BR0316746A BR0316746-1A BR0316746A BR0316746A BR 0316746 A BR0316746 A BR 0316746A BR 0316746 A BR0316746 A BR 0316746A BR 0316746 A BR0316746 A BR 0316746A
Authority
BR
Brazil
Prior art keywords
ferm
lineage
streptomyces
macrolide compound
mortierella
Prior art date
Application number
BR0316746-1A
Other languages
English (en)
Inventor
Akifumi Okuda
Satoshi Yamamoto
Takashi Sakai
Susumu Takeda
Takashi Nakashima
Katsura Kanebo
Tomohiro Sameshima
Taira Kato
Naoto Kawamura
Original Assignee
Mercian Corp
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercian Corp, Eisai Co Ltd filed Critical Mercian Corp
Publication of BR0316746A publication Critical patent/BR0316746A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO DE PRODUçãO DO COMPOSTO MACROLIDA 11107D, LINHAGEM STREPTOMYCES SP. AB-1704 (FERM BP-8551), LINHAGEM MORTIERELLA SP. F-1529 (FERM BP-8547) OU LINHAGEM F-1530 (FERM BP-8548), E LINHAGEM AB-1896 (FERM BP-8550)". A presente invenção proporciona um método de produzir o composto macrolida de anel constituído de 12 componentes 11107D que possui uma atividade antitumor mediante transformação biológica. O material de partida que é o composto macrolida de anel constituído de 12 componentes 11107B representado pela fórmula (I) é incubado em presença de uma linhagem pertencente ao gênero Mortierella, ao gênero Streptomyces ou à família Micromonosporaceae (por exemplo, linhagem Streptomyces sp. AB-1704 (FERM BP-8551)), cada um dos quais tema capacidade de transformar o composto macrolida de anel constituído de 12 componentes 11107B em uma substância 11107D representada pela fórmula (II), ou uma preparação de seus micélios cultivados e oxigênio e em seguida a substância 11107D que é um material alvo é coletado a partir da solução de tratamento.
BR0316746-1A 2002-11-29 2003-11-27 Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) BR0316746A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002346796 2002-11-29
PCT/JP2003/015170 WO2004050890A1 (ja) 2002-11-29 2003-11-27 マクロライド系化合物の製造方法

Publications (1)

Publication Number Publication Date
BR0316746A true BR0316746A (pt) 2005-10-18

Family

ID=32462862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316746-1A BR0316746A (pt) 2002-11-29 2003-11-27 Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)

Country Status (13)

Country Link
US (1) US7745198B2 (pt)
EP (1) EP1580278A4 (pt)
JP (1) JP4439401B2 (pt)
KR (1) KR20050086873A (pt)
CN (1) CN1717493A (pt)
AU (1) AU2003284469B2 (pt)
BR (1) BR0316746A (pt)
CA (1) CA2507641A1 (pt)
MX (1) MXPA05005672A (pt)
NO (1) NO20052568L (pt)
NZ (1) NZ540103A (pt)
RU (1) RU2330069C2 (pt)
WO (1) WO2004050890A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
WO2005052152A1 (ja) * 2003-11-27 2005-06-09 Mercian Corporation マクロライド系化合物の水酸化に関与するｄｎａ
AU2005265443B2 (en) * 2004-07-20 2008-09-04 Eisai R & D Management Co., Ltd DNA coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
JPWO2007043621A1 (ja) * 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法
US20090325978A1 (en) * 2006-08-14 2009-12-31 Katsumi Onai Stable lyophilized preparation
BRPI0805837A2 (pt) * 2007-01-29 2011-08-30 Eisai R&D Man Co Ltd forma sólida de um composto, método para preparação dos cristais, composição farmacêutica, método de tratamento de cáncer, e uso do composto sólido
BR112015025159A2 (pt) 2013-04-04 2017-07-18 Harvard College macrolídeos e métodos de sua preparação e uso
AU2015259237B2 (en) 2014-05-15 2019-08-15 Eisai R&D Management Co., Ltd. Pladienolide pyridine compounds and methods of use
WO2016057798A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
US10640528B2 (en) 2015-03-25 2020-05-05 President And Fellows Of Havard College Macrolides with modified desosamine sugars and uses thereof
JP6876680B2 (ja) 2015-09-01 2021-05-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
KR20180083376A (ko) 2015-11-18 2018-07-20 에자이 알앤드디 매니지먼트 가부시키가이샤 플라디에놀리드 피리딘 화합물의 고체 상태 형태 및 사용 방법
JP2020514348A (ja) 2017-03-15 2020-05-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライセオソーム変異及びその使用
EP3703755B1 (en) 2017-10-31 2024-07-31 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer
SG11202009906TA (en) 2018-04-09 2020-11-27 Eisai R&D Man Co Ltd Pladienolide compounds and their use
US11679107B2 (en) 2018-04-12 2023-06-20 Eisai R&D Management Co., Ltd. Certain aryl pladienolide compounds and methods of use
MX2020012940A (es) 2018-06-01 2021-03-25 Eisai R&D Man Co Ltd Metodos de uso de moduladores de empalme.
KR20230104204A (ko) 2020-11-04 2023-07-07 에자이 알앤드디 매니지먼트 가부시키가이샤 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법
CN114478257A (zh) * 2021-12-29 2022-05-13 福建省山河药业有限公司 一种抗肿瘤霉菌酸类化合物及其制备方法、应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352783A (ja) * 1991-05-27 1992-12-07 Taisho Pharmaceut Co Ltd １２員環マクロライド系化合物
AU5179800A (en) 1999-06-03 2000-12-28 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Mycolactone and related compounds, compositions and methods of use
US6562602B2 (en) 2000-08-03 2003-05-13 Kosan Biosciences, Inc. Fermentation and purification of mycolactones
TWI311558B (en) * 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
CA2494536C (en) * 2002-07-31 2011-10-04 Mercian Corporation A 12-membered ring macrolide active substance
JPWO2007043621A1 (ja) 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法

Also Published As

Publication number Publication date
NO20052568L (no) 2005-06-29
JP4439401B2 (ja) 2010-03-24
RU2330069C2 (ru) 2008-07-27
US20060141589A1 (en) 2006-06-29
CA2507641A1 (en) 2004-06-17
RU2005120390A (ru) 2006-01-27
MXPA05005672A (es) 2005-08-16
JPWO2004050890A1 (ja) 2006-03-30
EP1580278A1 (en) 2005-09-28
KR20050086873A (ko) 2005-08-30
AU2003284469B2 (en) 2008-02-21
NZ540103A (en) 2007-05-31
WO2004050890A1 (ja) 2004-06-17
EP1580278A4 (en) 2010-08-25
CN1717493A (zh) 2006-01-04
AU2003284469A1 (en) 2004-06-23
NO20052568D0 (no) 2005-05-27
US7745198B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
BR0316746A (pt) Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)
Vu et al. Antimicrobial and cytotoxic properties of bioactive metabolites produced by Streptomyces cavourensis YBQ59 isolated from Cinnamomum cassia Prels in Yen Bai Province of Vietnam
Hegazy et al. Microbial biotransformation as a tool for drug development based on natural products from mevalonic acid pathway: A review
Hur et al. Isolation of an anaerobic intestinal bacterium capable of cleaving the C-ring of the isoflavonoid daidzein
Indrianingsih et al. α-Glucosidase inhibitor produced by an endophytic fungus, Xylariaceae sp. QGS 01 from Quercus gilva Blume
Zhou et al. New azaphilones and tremulane sesquiterpene from endophytic Nigrospora oryzae cocultured with Irpex lacteus
Jiang et al. Conversion of puerarin into its 7-O-glycoside derivatives by Microbacterium oxydans (CGMCC 1788) to improve its water solubility and pharmacokinetic properties
Hara et al. Dehydropropylpantothenamide isolated by a co-culture of Nocardia tenerifensis IFM 10554 T in the presence of animal cells
Indananda et al. Linfuranone A, a new polyketide from plant-derived Microbispora sp. GMKU 363
Amin et al. Comparative studies of acidic and enzymatic hydrolysis for production of soyasapogenols from soybean saponin
Xie et al. Methylglucosylation of phenolic compounds by fungal glycosyltransferase-methyltransferase functional modules
Ibrahim et al. Microbial metabolism of biologically active secondary metabolites from Nerium oleander L.
Zotchev Unlocking the potential of bacterial endophytes from medicinal plants for drug discovery
Maatooq et al. Bioactive microbial metabolites from glycyrrhetinic acid
Wu et al. A new 2 H-benzindazole compound from Alternaria alternata Shm-1, an endophytic fungus isolated from the fresh wild fruit of Phellinus igniarius
Huang et al. New bioactive derivatives of nonactic acid from the marine Streptomyces griseus derived from the plant Salicornia sp.
Qin et al. Secondary metabolites of the zoanthid-derived fungus Trichoderma sp. TA26-28 collected from the south China sea
Lang et al. Improved production of bioactive glucosylmannosyl-glycerolipid by sponge-associated Microbacterium species
JP5283927B2 (ja) 新規化合物アミコラマイシン、その製造方法及びその用途
US4759928A (en) Antibiotic: Treponemycin
US6046041A (en) Method for producing marine-derived compounds and novel compounds produced therefrom
Wallace et al. The conversion of the 8-C-glycosylflavone vitexin to the 6-isomer, isovitexin, in Lemna minor
Niitsuma et al. Sinefungin VA and dehydrosinefungin V, new antitrypanosomal antibiotics produced by Streptomyces sp. K05-0178
WO2010122669A1 (ja) 新規化合物アミコラマイシン、その製造方法及びその用途
Cheng et al. Chemical constituents of metabolites produced by the Actinomycete Acrocarpospora punica

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCIAN CORPORATION (JP) , EISAI R AND D MANAGEMEN

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.